THE US Food and Drug
Administration has approved OSI
Pharmaceuticals’ Tarceva
(erlotinib) as a maintenance
treatment for patients with locally
advanced or metastatic non-small
cell lung cancer whose disease has
not progressed after four cycles of
first-line chemotherapy.
Tarceva is a once-daily pill which
is already FDA-approved for people
whose cancer has grown or spread
after receiving at least one course
of chemotherapy.
OSI ceo Colin Goddard said the
company was pursuing the study of
additional uses for Tarceva incl as
a first line lung cancer treatment, &
ovarian and hepatocellular cancer.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Apr 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Apr 10
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.